title: In vivo evaluation of plasmid DNA encoding OP-1 protein for spine fusion.
abstract: METHODS
  A posterolateral lumbar interbody arthrodesis animal model was selected to evaluate the percutaneous delivery of OP-1 plasmid DNA. OBJECTIVE.: To evaluate the feasibility of achieving ectopic bone formation using nonviral gene delivery with a minimally invasive technique, by coinjecting plasmid DNA encoding OP-1 with collagen into the paraspinal muscle.
  
  
  BACKGROUND
  Osteoinductive proteins show great promise for achieving spine fusion but suffer from poor bioavailability. Viral gene transfer can produce therapeutic and sustained levels of osteoinductive proteins to achieve osteogenesis in a variety of animal models. Toxicity and immunogenicity concerns, however, limit the appeal of viral gene therapy for spine fusion.
  
  
  METHODS
  Single-level posterior lumbar arthrodesis was attempted at L5-L6 in 64 adult Sprague-Dawley rats bilaterally. OP-1 plasmid DNA was injected with and without collagen carrier above the L5 transverse process either percutaneously or after open surgery. Bone formation was evaluated at 2 and 4 weeks by manual palpation, posterolateral radiographs, and nondecalcified histology. Control animals received the rhOP-1 protein.
  
  
  RESULTS
  Bone formation was detected histologically after the percutaneous and open surgical delivery of 25 microg or 500 microg, respectively, of OP-1 plasmid DNA (pVR1055-OP1) and collagen (bone formation = 75% and 50%), but was weaker than that observed after injection of 30 microg of rhOP-1 protein and collagen (bone formation = 100%). Single-level spine fusion was only achieved in groups receiving percutaneous OP-1 protein and collagen (30 microg protein, fusion rate = 100%) or high concentrations of OP-1 protein alone (40 microg protein, 100%), as confirmed through manual palpation, histology, and radiography. CONCLUSIONS.: These data confirm that OP-1 plasmid DNA can successfully generate bone formation in vivo.
authors.affiliation: Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Corinne
authors.initials: C
authors.lastname: Bright
authors.forename: Ye-Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Ann N
authors.initials: AN
authors.lastname: Sieber
authors.forename: John P
authors.initials: JP
authors.lastname: Kostuik
authors.forename: Kam W
authors.initials: KW
authors.lastname: Leong
mesh_terms: D000818:Animals; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology*; D004247:DNA; D005240:Feasibility Studies; D005822:Genetic Vectors; D008159:Lumbar Vertebrae; D008297:Male; D023421:Models, Animal; D018482:Muscle, Skeletal; D010012:Osteogenesis / Q000187:drug effects*; D010957:Plasmids; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology*; D013123:Spinal Fusion / Q000379:methods*
chemical_list: C525821:Bmp7 protein, rat; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D003094:Collagen; D004247:DNA